Turkish daily Yeni Safak recently quoted Afsin Emre Kayipmaz, a member of the scientific council on COVID-19 of the country, as saying that the trials of the Sputnik V vaccine were conducted in Turkey. and the company applying for production has also been licensed.
|Turkey will produce the Russian vaccine and sell it for $ 10 a dose.|
“The price of Russian vaccine in Turkey will be about 10 USD” – the newspaper quoted Mr. Kayipmaz said.
Earlier, on January 23, the representative of the Russian Direct Investment Fund (RDIF) announced that they had reached an agreement with a leading Turkish pharmaceutical manufacturer to produce Sputnik V. in this country. According to this representative, the technology transfer process has been implemented.
Mr. Ozturk Oran, Chairman of the board of Turkish pharmaceutical manufacturing company VisCoran Ilac Sanayii AS announced that his company is ready to produce millions of doses of Sputnik V vaccine after completing the process of technology transfer. between two countries.
In early April, Russia reached an agreement with 20 manufacturers in 10 countries around the world to produce Sputnik V vaccine against Covid-19.
“We have agreements with 20 manufacturers in 10 countries, including the major vaccine manufacturers around the world. India and Korea already produce our vaccines. There will be more of our vaccine manufacturing units from this April, ”said an RDIF representative.
According to the head of the Russian Direct Investment Fund, with this agreement, in the coming time, more Russians and people around the world will have the opportunity to be vaccinated against Covid-19 in the context of demand. pandemic vaccine is enormous.
Before that, Gamaleya Center was ready to share its vaccine purification technology with other developers to minimize the risk of side effects.
It should be noted that based on the results of analysis of the results of clinical trials and mass vaccination with Sputnik V, no cases of venous sinus thrombosis have been reported in the human brain. During the production of Sputnik V, a purification technology is used consisting of two phases of chromatographic refinement and two stages of tangent filtration.
Any vaccines based on adenoviral virus vectors have specific features, and it would not be correct to compare vaccines developed based on vector technology in Russia directly with others in the world, the Center explained. gender. In addition to Sputnik V, the AstraZeneca and Johnson & Johnson vaccines have also been developed based on this technology.
It is estimated that 58 countries around the world have licensed the Sputnik V. Vaccine to be registered in Russia in August 2020 before being included in the large-scale clinical trial. The safe and effective level of vaccine up to 90% has been recognized and published by the world’s leading medical journal The Lancet.
By May, representatives of the European Pharmaceutical Agency will also travel to Russia to inspect the production and testing processes of the Sputnik V vaccine before licensing the vaccine in Russia.